Search

Your search keyword '"Thromboangiitis Obliterans pathology"' showing total 340 results

Search Constraints

Start Over You searched for: Descriptor "Thromboangiitis Obliterans pathology" Remove constraint Descriptor: "Thromboangiitis Obliterans pathology"
340 results on '"Thromboangiitis Obliterans pathology"'

Search Results

1. Identification of S100A8/A9 involved in thromboangiitis obliterans development using tandem mass tags-labeled quantitative proteomics analysis.

2. Recent advances of oxidative stress in thromboangiitis obliterans: biomolecular mechanisms, biomarkers, sources and clinical applications.

3. Atypical Young-onset Dementia in Cerebral Thromboangiitis Obliterans: A Case Report.

4. Thromboangiitis Obliterans (Buerger's Disease) in an Adolescent Male.

5. MiR-223 alleviates thrombus and inflammation in thromboangiitis obliterans rats by regulating NLRP3.

6. Cotinine aggravates inflammatory response in thromboangiitis obliterans through TLR-4/MyD88/NF-κB inflammatory signaling pathway.

7. [56-year old patient with acroasphyxia].

9. Visceral bed involvement in thromboangiitis obliterans: a systematic review.

10. Angiogenesis induction in Buerger's disease: a disease management double-edged sword?

11. Outcomes of endovascular treatment versus bypass surgery for critical limb ischemia in patients with thromboangiitis obliterans.

13. Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger's disease).

14. Autologous bone marrow-derived mononuclear cell therapy in Chinese patients with critical limb ischemia due to thromboangiitis obliterans: 10-year results.

15. Multi-organ vaso-occlusive disease: Buerger's or Kohlmeier-Degos disease?

16. Rickettsia infection could be the missing piece of the Buerger's disease puzzle.

17. Administration of Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger's Disease: Phase II Study Report Suggests Clinical Efficacy.

19. [Cerebral manifestations of thromboangiitis obliterans. Case report].

20. A case of refractory IgG4-related peripheral neuropathy with severe axonal damage.

21. [THROMBOANGIITIS OBLITERANS OVERLAPPING WITH ATHEROSCLEROTIC OCCLUSIVE ARTERIAL DISEASE: SMALL MESENTERIC ARTERY INVOLVEMENT BY THROMBOANGIITIS OBLITERANS].

22. Hypoxia-inducible factor-1α expression in the different stages of rat thromboangiitis obliterans.

23. Thromboangiitis obliterans - case report.

24. Integrated treatment for lower-limb stage II thromboangiitis obliterans by interventional therapy and oral administration of Chinese medicine: a randomized controlled clinical trial.

25. Beperminogene perplasmid for the treatment of critical limb ischemia.

26. A disease-specific activity score for Thromboangiitis obliterans.

27. Quiz 3/2014.

28. Clinical, arteriographic and histopathologic analysis of 13 patients with thromboangiitis obliterans and coronary involvement.

29. Quiz 4/2014.

30. Embolus-carried vascular endothelial cell growth factor 165 improves angiogenesis in thromboangiitis obliterans.

31. Effect of Ocimum basilicum L. on cyclo-oxygenase isoforms and prostaglandins involved in thrombosis.

32. Endarteritis obliterans in the pathogenesis of Buerger's disease from the pathological and immunohistochemical points of view.

33. Reduced circulating endothelial progenitor cells in thromboangiitis obliterans (Buerger's disease).

34. Smoker with Raynaud phenomenon and painful nodules on the legs.

35. Temporal artery involvement as the presenting sign of thromboangiitis obliterans.

36. Assessment of plasma prothrombotic factors in patients with Buerger's disease.

37. A stable prostacyclin analogue (iloprost) in the treatment of Buerger's disease: a prospective analysis of 150 patients.

38. Impaired endothelial-dependent and endothelium-independent vasodilatation in patients with thromboangiitis obliterans.

39. Endovascular treatment is a hope for patient with Buerger's disease and foot ulcer: case report.

40. Circulating angiogenic factors in patients with thromboangiitis obliterans.

41. Immunohistochemical properties in the patients with Buerger's disease--possible role of plasminogen activator inhibitor-1 for preservation of vessel wall architecture.

42. Images in clinical medicine. Dependent rubor.

43. Early outgrowth EPCs generation is reduced in patients with Buerger's disease.

44. Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society.

45. Buerger disease (thromboangiitis obliterans): a clinical diagnosis.

46. Pot shots-Cannabis arteritis of the digits.

47. Establishment of culturing system for ex-vivo expansion of angiogenic immature erythroid cells, and its application for treatment of patients with chronic severe lower limb ischemia.

48. Classification of corkscrew collaterals in thromboangiitis obliterans (Buerger's disease): relationship between corkscrew type and prevalence of ischemic ulcers.

49. Targeting novel antigens in the arterial wall in thromboangiitis obliterans.

50. Thromboangiitis obliterans with multiple large vessel involvement: case report and analysis of immunophenotypes.

Catalog

Books, media, physical & digital resources